Spondyloarthropathies News

Most patients with recent-onset chronic back pain suspected of axial spondyloarthritis can be “unequivocally and reliably diagnosed” at their first rheumatology visit, according to data published in the Annals of the Rheumatic Diseases.

An initiative to switch clinically stable patients from Remicade to a biosimilar significantly increased biosimilar use in rheumatology and gastroenterology clinics within the University of North Carolina health system, according to data.

Fatigue in patients with inflammatory rheumatic and musculoskeletal diseases should be addressed with tailored physical activity, psychoeducational interventions or possibly immunomodulatory treatment, according to EULAR recommendations.

The FDA has approved an abbreviated new drug application from ANI Pharmaceuticals for indomethacin oral suspension, a generic version of Indocin oral suspension, according to a press release from the manufacturer.

Poverty and chronic inflammation together may have a “synergistic” impact leading to higher all-cause mortality, including a 127% increased heart disease mortality risk and a 196% higher risk for cancer mortality, according to data.

CVS Caremark, one of the nation’s largest pharmacy benefit managers, will remove Humira from its major national commercial formularies effective April 1 in favor of biosimilar options, according to a press release from the company.

Patients reported low overall satisfaction with New Zealand’s mandatory nationwide transition to an adalimumab biosimilar, though most said they are still taking it and appreciated its less-painful injections, according to a study.

SAN DIEGO — In patients with chronic rheumatic inflammatory disease, those who continue TNF inhibition during pregnancy have similar obstetrical outcomes as those who cease treatment, according to data presented at ACR Convergence 2023.

SAN DIEGO — COVID-19 vaccine boosters led to a significantly increased antibody response in patients using abatacept or TNF inhibitors regardless of whether they held medication, according to data presented at ACR Convergence 2023.

Following HHS’ blockbuster announcement of the first 10 drugs that would be subject to Medicare price negotiations, patients and providers alike have been looking forward to meaningful reductions in their costly treatments.